

You can do more  
than manage OA.  
**You can treat it.**

DISCOVER IF **ADEQUAN® CANINE** IS THE  
RIGHT CHOICE FOR YOUR PATIENTS.



## The difference between feeling better and **getting better.**®

With Adequan® Canine (polysulfated glycosaminoglycan), you have a way to proactively treat canine osteoarthritis (OA) and not just manage or control clinical signs of the disease. **It's the only FDA-approved disease-modifying osteoarthritis drug (DMOAD) that's been clinically proven to treat canine OA.**<sup>1</sup> Adequan® Canine is recommended for intramuscular injection for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.

THE DIFFERENCE IS  
PROVEN RELIEF AND  
RELIABLE PROTECTION  
THAT MAY HELP TO:<sup>1</sup>

- Restore joint lubrication
- Relieve inflammation
- Renew the building blocks of healthy cartilage

The specific mechanism of action of Adequan® in canine joints is not known.<sup>1</sup>

## Adequan® Canine is the **only treatment** that helps slow down the clock on OA.

- Once canine OA begins (and it's not just an "old-dog" problem), the clock starts ticking.
- Without treatment, deterioration of joint cartilage, surrounding tissue and fluid will go unchecked; leading to bone-on-bone contact, chronic inflammation, and loss of mobility.<sup>2</sup>

Starting treatment early with Adequan® Canine can help slow progression of the disease. **Please see Important Safety Information on the reverse side.**

 **Adequan Canine®**  
polysulfated glycosaminoglycan

# Adequan® Canine is the only drug that has been shown to help slow down the damage caused by canine OA.

Product Features	Adequan® Canine*	Joint Supplements**	NSAIDs	Medical Devices**
Only FDA-approved disease-modifying osteoarthritis drug (DMOAD) <sup>1</sup>	✓	✗	✗	✗
FDA-reviewed studies with proven efficacy results for treating the OA disease process in dogs <sup>1</sup>	✓	✗	✗	✗
Diffuses into the joints and helps rebuild cartilage <sup>1</sup>	✓	✗	✗	✗
Proven to inhibit catabolic enzymes and promote anabolic activity in the synovial joints <sup>1</sup>	✓	✗	✗	✗
Proven to reduce inflammation	✓	✗	✓	✗
Veterinary prescription only	✓	✗	✓	✗
Adherence to FDA-label requirements	✓	✗	✓	✗
Long-standing safety profile and post-approval monitoring and reporting of adverse events with FDA	✓	✗	✓	✗

\*The specific mechanism of action of Adequan® in canine joints is not known.

\*\*Not FDA-approved.

All products have the potential for adverse events that should be considered in overall management of any disease.



**Important Safety Information** Adequan® Canine should not be used in dogs who are hypersensitive to polysulfated glycosaminoglycan (PSGAG) or who have a known or suspected bleeding disorder. It should be used with caution in dogs with renal or hepatic impairment. Adverse reactions in clinical studies (transient pain at injection site, transient diarrhea, and abnormal bleeding) were mild and self-limiting. In post approval experience, death has been reported in some cases; vomiting, anorexia, depression/lethargy and diarrhea have also been reported. The safe use of PSGAG in breeding, pregnant or lactating dogs has not been evaluated. **Caution:** Federal law restricts this drug to use by or on the order of a licensed veterinarian. For additional safety information, please see Full Prescribing Information at [adequancanine.com](http://adequancanine.com).



Scan here to view the Adequan® Canine mode of action video.

FOR MORE INFORMATION:



1-800-458-0163



[adequancanine.com](http://adequancanine.com)

1. Adequan® Canine (polysulfated glycosaminoglycan), Package Insert. American Regent, Inc.
2. 2016 NAVC Proceedings, Osteoarthritis in Dogs and Cats: Novel Therapeutic Advances, M Epstein, DVM, DABVP C/F, CVPP; K Kirkby Shaw, DVM, MS, PhD, DACVS, DACVSMR.